This site is provides a program that you can use to help make healthful changes in your eating and exercise habits designed to help prevent cardiovascular disease.
The story of New Zealand six-time cancer survivor Phil Kerslake. Describes his inspiring life story, having battled both Hodgkin's and non-Hodgkin's lymphomas over 26 years. Details his chemotherapy, radiotherapy, eight operations including his spleen removal and host of other challenges along the way to his final full remission. Also describes his 2006 book about how to get mind, body and spirit aligned to recovery: Life, happiness ... and cancer: survive with action and attitude! (author's website at www.lifepaths.co.nz).
According to a study by Dr. Holly Gallion, published in the International Journal of Gynecological Cancer (IJGC) researchers using the Chemo FX Assay by Precision Therapeutics, identified which chemo agent would be most lethal to an individual patient's cancer. In the study of 256 women with recurrent ovarian cancer, the time women went before a worsening of their disease was two to three times longer if they were treated with an assay-sensitive drug compared to an assay-resistant drug. The bottom line is the assay is able to predict the patient's response to treatment. The Chemo FX is a (cell-death) assay test. Their study adds to the already large body of evidence of the accuracy of cell culture assays in ovarian cancer.
The assay determines which agents are most potent against a specific tumor and what concentration works best. No more hit or miss in the patient. Armed with that information, the treating physician and patient can proceed with a chemo regimen likely to work right out of the gate and subjecting the patient to less toxicity. If the assay finds that the tumor responds to none of the currently avialable treatments, a patient could then be referred to a clinical trial before a history of less useful treatments rules her out as a clinical trial candidate.
In light of the precious little in the way of guidance from clinical trials with respect to best empiric treatment, oncologists give treatments knowing full well that only a certain percentage of patients will receive a benefit from any given medicine. They subject patients to one combination chemotherapy after another, just going from one journal paper to another journal paper. They need information about the characteristics that predict which patients are more likely to respond well. The empirical approach, which is based on medical journal articles, epidemiology and economics, doesn't tell doctors how to personalize their care to individual patients. Physicians' decisions need to be based on personal experience, clinical insights, and medical training.
Cell culture assay measures the net effect of all processes within the cancer, acting with and against each other in real time, and it tests living cells actually exposed to drugs and drug combinations of interest. Tens of thousands of individual patient specimens are currently being submitted for testing by more than 1,000 clinical oncologists, surgeons and pathologists annually in the U.S. It is certainly each practitioner's prerogative to order these tests. It seems probable that a self-educated oncologist, genuinely on the cutting-edge would tend to be aggressive in actual treatment beyond mere rhetoric, and make use of running tests on a "fresh" tumor specimen before selecting a chemotherapy option.
Gallion, H. H., W. A. Christopherson, et al. (Jan/Feb 2006). "Relationship between ex vivo chemosensitivity assay and progression free interval in ovarian cancer." International Journal of Gynecological Cancer
PubMed lists a paper that reports an increase from 35% to 65% response rate for recurrent ovarian cancer patients when cell culture assay tests were used to select the chemotherapy drugs. The P values (P=.005, etc.) given are measures of the statistical significance of the findings. The smaller the number, the higher the statistical significance. "P" refers to the probability that the finding is due to random chance. So, high P values are bad. P values of 5% or less are deemed to be statistically significant. All of the P values reported in this study indicate that the results are, indeeed, statistically significant.
(Am J Obstet Gynecol. 2003 Nov;189(5):1301-7)
This is an amazing and empowering 3 to 4 minute
movie which chronicles the lives of all of us touched by cancer...the fighter and the caregiver alike. I highly recommend it to give us all the boost of confidence, courage, and compassion we need to keep going! Be Stronger Than, Not Angry At...Chenheart
This is a wonderful mentoring site started by one of "our own" from CSN; Ceezhar! If you click on A Poem Grows, you will find a series of poems she and I wrote to one another. I hope you find reading them as uplifting as we did writing them! Be Stronger Than, Not Angry At! Love, Chenheart
Every month, Cancer Monthly summarizes the latest clinical results of cancer therapies presented by oncologists, researchers, and other cancer professionals working in over 340 hospitals and research institutions around the world. With this information, patients can compare treatments, have more meaningful discussions with their doctors, and ultimately, make more informed treatment decisions.
If your current Doctor hasn't done it, do it yourself (then find a better doctor)
A simple lab test that could customize chemotherapy to the patient and save lives. When science takes a back seat: public posturing, private bargains, and scandal, set in the cancer industry.
The medical-political backdrop and wrangling over technology. Literary realism (clinical trials, informed consent)
Privately, as a student of Cell Function Analysis, I can say the "science" in this book is very real.
Loss of hair due to chemotherapy is not easy to deal with. One person may accept new looks, another may wish to have a full head of hair again. Wearing a wig is as close as one can get to having that. Come to our website for a variety of breathable, lightweight human hair wigs and hairpieces.
This is a national movement to raise awareness of the nearly 46 million Americans living without health coverage along with initiatives leading to access.